Continuing Education Activity

This activity provides an in-depth review of calcitriol, a hormonally active synthetic vitamin D analog prescribed to manage hypocalcemia and renal osteodystrophy. FDA-approved indications include treating hypocalcemia in patients undergoing chronic renal dialysis, secondary hyperparathyroidism in those with chronic kidney disease not yet requiring dialysis, and hypocalcemia in patients with hypoparathyroidism or pseudohypoparathyroidism. The activity examines the mechanism of action, administration routes, and pharmacokinetics of calcitriol, along with strategies for effective monitoring to optimize therapeutic outcomes.

Significant adverse events, contraindications, and clinically relevant drug-drug interactions are discussed to support safe prescribing practices. A review of calcitriol’s toxicological profile and strategies to minimize adverse effects is also included to enhance patient safety. Additionally, collaboration within the interprofessional healthcare team is emphasized to individualize treatment plans and improve patient outcomes when using calcitriol for indicated conditions.

Objectives:

• Evaluate the mechanism of action of calcitriol.
• Identify the FDA-approved indications and off-label uses of calcitriol.
• Screen for contraindications and risks associated with calcitriol therapy.
• Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from calcitriol therapy.

Indications

Calcitriol is a hormonally active, synthetic vitamin D analog prescribed to treat hypocalcemia, osteoporosis, and the prevention of corticosteroid-induced osteoporosis.[1]

FDA-Approved Indications

Systemic calcitriol is FDA-indicated to control hypocalcemia in patients on chronic renal dialysis, secondary hyperparathyroidism in patients with chronic kidney disease not yet on dialysis, and hypocalcemia in patients with hypoparathyroidism and pseudohypoparathyroidism.[2][3][4] In 2009, the FDA approved topical calcitriol ointment to manage mild to moderate plaque psoriasis.[5] According to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, for patients with chronic kidney disease stage 5 on dialysis (CKD G5D) requiring parathyroid hormone (PTH)-lowering therapy, it is suggested to use calcimimetics, calcitriol, or vitamin D analogs. Additionally, in patients within the first 12 months after kidney transplant, with an estimated glomerular filtration rate greater than approximately 30 mL/min/1.73 m² and low bone mineral density (BMD), treatment with vitamin D, calcitriol, or alfacalcidol should be considered. For pediatric patients, calcitriol may be considered to maintain serum calcium levels within the age-appropriate normal range.[6] According to the Joint American Academy of Dermatology–National Psoriasis Foundation Guideline, topical vitamin D analogs (such as calcitriol) for up to 52 weeks is recommended for mild to moderate psoriasis. However, combination treatments with vitamin D analogs and topical corticosteroids from 3 to 52 weeks are more effective than either agent alone.[7] Alfacalcidol and calcitriol effectively maintain calcium levels and physiological 1,25-dihydroxyvitamin D levels in hypoparathyroidism. However, calcitriol is more potent than alfacalcidol.[8]

Off-Label Uses

Off-label uses for systemic calcitriol include type 1, vitamin D-dependent rickets, or pseudo-vitamin D deficiency rickets.[9][10] Calcitriol is also used off-label for X-linked hypophosphatemia, known as vitamin D-resistant rickets.[11] Off-label use of topical calcitriol ointment includes psoriasis in children and adolescents.[12] Calcitriol has been studied in patients with Friedreich ataxia (FRDA) at a minimum dose of 0.25 μg daily, increasing frataxin levels with minimal adverse effects. However, no significant neurological improvement was observed. Future trials with higher doses, larger patient groups, and longer treatment durations could provide more insight. However, the study had a small sample size, was open-label without a placebo, and excluded 5 patients due to mild hypercalcemia.[13] A study comparing calcipotriol and calcitriol in combination with narrow-band ultraviolet B phototherapy for stable plaque psoriasis showed both treatments effective, with calcipotriol demonstrating earlier plaque clearance and fewer treatment sessions.[14]

Mechanism of Action

In humans, vitamin D3 is the primary form of vitamin D, synthesized from 7-dehydrocholesterol when exposed to sunlight. Vitamin D3 can also be obtained through dietary sources or supplements. Once in the bloodstream, vitamin D3 binds to vitamin D-binding protein (DBP) and is transported for activation in the liver and kidneys. In the liver, vitamin D3 undergoes conversion by enzymes in the cytochrome P450 system to form 25-hydroxyvitamin D. This molecule is further converted in the kidneys by the enzyme 1-α hydroxylase into 1,25-dihydroxyvitamin D (calcitriol), the active form of vitamin D. Calcitriol, a small lipophilic molecule with superior cellular penetration, then binds to the vitamin D receptor (VDR).[15]

Calcitriol binds to vitamin D receptors in the kidneys, parathyroid glands, intestines, and bones to increase serum blood calcium levels by promoting absorption in the intestines, renal tubular reabsorption in the kidneys, and release from bone. Calcitriol is also a transcription factor that encodes a calcium-binding protein, simultaneously transporting calcium and phosphate ions across intestinal epithelial cells.[3] Along with the parathyroid hormone, calcitriol stimulates bone resorption by activating osteoclasts and releasing the receptor activator of nuclear factor κB ligand (RANKL) from osteoblasts. Topically, studies have found that calcitriol significantly inhibits the proliferation of normal human epidermal keratinocytes and T lymphocytes by inducing apoptosis and inhibiting gene expression of relevant chemokines and epidermal proteins involved in psoriasis.[4]

Pharmacokinetics

Absorption: Calcitriol is quickly absorbed from the intestine. Peak serum concentrations are attained within 3 to 6 hours, and the steady-state plasma concentration is achieved within 7 days.

Distribution: Calcitriol is approximately 99.9% bound in plasma. An α-globulin vitamin D binding protein facilitates the transportation of calcitriol and other vitamin D metabolites in the blood. Furthermore, calcitriol is transferred into human breast milk at low concentrations. Maternal calcitriol is capable of entering fetal circulation.

Metabolism: There are 2 pathways of metabolism for calcitriol. The first pathway involves the enzyme 24-hydroxylase as the first step in its catabolism. The end product of this pathway is calcitroic acid. The second pathway converts calcitriol via stepwise hydroxylation and cyclization to yield calcitriol lactone, which is the major metabolite.[16][17]

Elimination: Enterohepatic recycling and biliary excretion of calcitriol occur. The metabolites of calcitriol are excreted primarily in feces. A study shows that vitamin D deficiency promotes the progression of nonalcoholic steatohepatitis/metabolic dysfunction-associated steatotic liver disease (NASH/MASLD) by disrupting the enterohepatic circulation of bile acids, leading to impaired bile acid retention in the liver, increased hepatic lipogenesis, and inflammation. Restoration of 1,25-dihydroxyvitamin D3 (calcitriol) or bile acid sequestration may offer potential therapeutic strategies for treating or preventing MASLD disease by improving bile acid circulation and reducing liver inflammation.[18][19]

Administration

Available Dosage Forms and Strengths

Calcitriol may be administered intravenously through a catheter, orally without regard to meals, or topically for external use only. No dilution is necessary for intravenous administration, and a bolus dose is given at the end of a hemodialysis session. During the initial titration period, serum calcium and phosphorus levels should be monitored twice weekly. Calcitriol capsules and oral solutions may be taken with or without meals but should be protected from prolonged light exposure. Topical administration is performed by applying a thin film to the affected area with gentle rubbing, being careful not to apply to the face or eyes. Topical calcitriol is available as an ointment containing 3 μg of calcitriol per gram. Systemic calcitriol is available as oral capsules in 0.25 and 0.5 μg, an injectable 1 μg/mL solution, and an oral solution of 1 μg/mL.

Adult Dosage

Dialysis-associated hypocalcemia: The initial dose of calcitriol is 0.25 μg/d, which may be increased by 0.25 μg/d every 4 to 8 weeks. Serum calcium levels should be monitored twice weekly during titration and monthly once the optimal dose is reached. Most patients respond to doses between 0.5 μg/d and 1 μg/d.

Hypoparathyroidism: The recommended initial dose is 0.25 μg/d. The dose can be increased at 2 to 4 weeks based on response. During titration, serum calcium levels should be monitored twice weekly. Most adult and pediatric patients respond to a dosage between 0.5 and 2 μg daily, while younger patients (aged 1 to 5) typically receive between 0.25 μg to 0.75 μg daily.

Secondary hyperparathyroidism: The initial dose of calcitriol is 0.25 μg/d, which may be increased to 0.5 μg/d if necessary. The initial dosage for pediatric patients younger than 3 is 10 to 15 ng/kg/d.

Psoriasis: For psoriasis, patients should be instructed to apply calcitriol topical ointment to affected areas twice daily. The maximum weekly dose for adults is 200 g.

Specific Patient Populations

Hepatic impairment: Studies investigating the impact of hepatic impairment on calcitriol have not been conducted. Use with caution.

Renal impairment: Lower peak calcitriol levels in serum have been observed in patients with nephrotic syndrome and those undergoing hemodialysis compared to healthy individuals. The elimination half-life of calcitriol is significantly prolonged in patients with chronic kidney disease and hemodialysis.

Pregnancy considerations: Calcitriol is considered a FDA Pregnancy Category C drug, meaning there are no well-controlled studies on the adverse effects of calcitriol on pregnant women. In cases where calcitriol is necessary for pregnant women, close monitoring of serum calcium levels is required since pregnancy is associated with alterations in calcium production, metabolism, and excretion.[20] Further adverse effects, including neonatal mental retardation and congenital aortic stenosis, must be considered as potential outcomes of hypercalcemia during pregnancy.

Breastfeeding considerations: Calcitriol, the active form of vitamin D (1,25-dihydroxyvitamin D), has been used safely by women with hypocalcemia during breastfeeding despite occasional fluctuations in serum calcium levels. Limited evidence suggests that appropriately adjusted doses of calcitriol do not harm breastfed infants. If a mother needs calcitriol, breastfeeding does not need to be discontinued. Additionally, women with hypoparathyroidism often require lower doses of calcitriol and calcium when lactating.[21] On that note, lactating mothers must also be closely monitored for hypercalcemia due to post-partum and potential lactation-induced alterations in calcium metabolism.[22]

Pediatric patients: The safety and effectiveness of calcitriol in pediatric dialysis patients are not established. Adult studies and pediatric data support its use in predialysis pediatric patients. Dosing guidelines are unavailable for pediatric patients younger than 12 months with hypoparathyroidism or younger than 6 years with pseudohypoparathyroidism. Oral doses of 10 to 55 ng/kg/d improve calcium homeostasis and bone disease in predialysis pediatric patients. Long-term use is well tolerated, with common issues like mild hypercalcemia and hyperphosphatemia managed by dose adjustments or temporary discontinuation. Children with psoriasis (and their caregivers) should be instructed to apply calcitriol topical ointment to affected areas twice daily. For children aged 2 to 6 years, the maximum weekly dose is 100 g. For children aged 7 and older, the maximum weekly dose is 200 g.  

Older patients: Calcitriol should be administered cautiously in older patients, starting at the lower end of the dosing due to the risk of reduced renal function and concomitant diseases or medications. No significant differences in response between older and younger patients have been reported.

Adverse Effects

Hypercalcemia is the most common adverse reaction reported in at least one-third of patients taking systemic calcitriol. Early signs of hypercalcemia include fatigue, weakness, nausea, vomiting, abdominal pain, constipation, diarrhea, vertigo, tinnitus, ataxia, arthralgia, and irritability.[23] Late signs of hypercalcemia include polyuria, polydipsia, cardiac arrhythmias, sensory disturbances, apathy, nephrocalcinosis, urinary tract infections, and hypertension.

Less than 10% of reported adverse reactions include headache, skin rash, polydipsia, nausea, abdominal pain, and urinary tract infection. Less than 1% include hypertension, increased hematocrit, increased hemoglobin, drowsiness, hyperthermia, lymphocytosis, increased neutrophils, anorexia, constipation, and ophthalmic conditions such as conjunctivitis and photophobia.

Hypercalciuria and nephrolithiasis have been confirmed in patients receiving systemic calcitriol treatment. Laboratory abnormalities associated with late signs of hypercalcemia include elevated aspartate aminotransferase (AST), alanine aminotransferase (ALT), and blood urea nitrogen (BUN) levels. Because calcitriol also increases the intestinal absorption of phosphorous, hyperphosphatemia can occur in patients with renal failure and may further contribute to elevated serum creatinine levels, ectopic calcification, secondary hyperparathyroidism, and renal osteodystrophy.

Hypersensitivity reactions, including pruritus, rash, and urticaria, may occur in susceptible patients. Studies of intravenous calcitriol have found rare cases of anaphylactoid reactions attributed to systemic calcitriol [24]. Less than 1% of post-marketing case reports have found pruritus, erythema, acute generalized exanthematous pustulosis, psoriasis, and contact dermatitis associated with calcitriol ointment administration.

Drug-Drug Interactions

Cholestyramine: Cholestyramine may impair the absorption of fat-soluble vitamins, including calcitriol, decreasing their effectiveness. Therefore, monitoring for deficiencies and adjusting treatment as needed is essential.

Phenytoin/phenobarbital: Phenytoin or phenobarbital does not significantly affect plasma concentrations of calcitriol but may decrease the endogenous plasma levels of 25-hydroxyvitamin D3 by accelerating its metabolism. Therefore, higher doses of calcitriol may be required when these drugs are used concomitantly.

Thiazides: Thiazides can induce hypercalcemia by decreasing renal calcium excretion. When co-administered with calcitriol, thiazides may exacerbate hypercalcemia. Caution is warranted when coadministering these agents.

Digitalis: Caution should be exercised when administering calcitriol to patients receiving digitalis, as hypercalcemia may increase the risk of arrhythmias. Close monitoring of calcium levels is essential to avoid complications.

Ketoconazole: Ketoconazole may inhibit both the synthesis and catabolism of calcitriol, reducing serum calcitriol levels.

Corticosteroids: Corticosteroids may act as functional antagonists to calcitriol. They inhibit calcium absorption in the gastrointestinal tract, which could reduce calcitriol's effectiveness in promoting calcium homeostasis.

Phosphate-binding agents: Given that calcitriol influences phosphate transport in the intestines, bones, and kidneys, adjustments in the dosage of phosphate-binding agents may be necessary, depending on the patient's serum phosphate levels. Patients with chronic kidney disease who take aluminum-containing antacids for hyperphosphatemia must also be monitored closely, as the calcium-phosphate product may affect serum calcium and phosphate levels.

Vitamin D: Calcitriol is the most potent active form of vitamin D3; concurrent administration of vitamin D and its analogs should be avoided to prevent potential additive effects and the risk of hypercalcemia.

Calcium supplements: Excessive intake of calcium-containing preparations should be avoided during calcitriol therapy, as it may increase the risk of hypercalcemia.

Magnesium: Patients on dialysis should avoid magnesium-containing preparations, such as antacids, during calcitriol treatment due to the risk of hypermagnesemia.

Orlistat: Orlistat inhibits lipase, reducing the absorption of fat-soluble vitamins. Use caution and instruct the patient to take fat-soluble vitamins and separate doses adequately.[25]

Contraindications

Hypercalcemia, vitamin D toxicity, and hypersensitivity to calcitriol or any vitamin D analog are contraindications to taking systemic calcitriol.

Warning and Precautions

Relative contraindications to calcitriol include patients with increased sensitivity to calcium dysregulation, including arteriosclerosis, cardiac disease, hyperphosphatemia, renal failure, and sarcoidosis. Patients with cardiac disease, especially those taking digoxin, are at an increased risk for cardiac arrhythmias from hypercalcemia and should be dosed conservatively.[26] Patients with renal failure are susceptible to increased risk for vitamin D-induced hypercalcemia, and chronic hypercalcemia may lead to soft tissue calcification, nephrocalcinosis, and other toxicities.

From a preventative lifestyle perspective, accidental exposure, prolonged ultraviolet (UV) sunlight absorption, occlusive dressing use, ocular exposure, and dehydration are contraindications to calcitriol use, as they may increase serum calcium to toxic levels. Photosensitizing agents and UV sunlight may increase the risk of skin tumor formation when combined with topical calcitriol. The topical ointment should not be applied to the face, which may lead to skin irritation. For patients with recent injuries and wounds, increased calcium levels may also occur with topical administration due to the enhanced absorption of calcitriol from occlusive dressings.

As per Endocrine Society guidelines, ectopic production of calcitriol is a less frequent but significant cause of hypercalcemia of malignancy (HCM), particularly in lymphomas. Calcitriol-induced HCM increases calcium and phosphorus absorption from the gastrointestinal tract and enhances osteoclast-mediated bone resorption. Despite glucocorticoid therapy inhibiting the 1α-hydroxylase enzyme to limit calcitriol production, hypercalcemia may persist in these patients. In such cases, adding an intravenous bisphosphonate or denosumab is recommended to manage severe or symptomatic hypercalcemia effectively.[27]

Lymphomas or certain granulomatous diseases like sarcoidosis may activate extrarenal 1α-hydroxylase, the enzyme responsible for converting 25-hydroxyvitamin D to calcitriol. This leads to elevated calcitriol levels and hypercalcemia of malignancy, which should be separated from iatrogenic administration.[28]

Monitoring

Monitoring parameters for calcitriol involve measurements of serum calcium, creatinine, BUN, intact PTH, and phosphate. All patients must be monitored with serum calcium twice weekly during titration periods. According to the KDIGO 2009 guidelines, the corrected total serum calcium and phosphorus levels should be in the normal range for all stages of chronic kidney disease (CKD).[29] For patients with CKD stage 3, serum calcium and phosphorous levels should be monitored every 6 to 12 months. For CKD stage 4, serum calcium and phosphorous levels should be monitored every 3 to 6 months and PTH every 6 to 12 months. For CKD stage 5, serum calcium and phosphorous levels should be monitored every 1 to 3 months and PTH every 3 to 6 months. The literature is unclear on the optimal range for PTH levels in CKD, but in patients with CKD stage 5D, the careful maintenance of intact PTH levels should be within 2 to 9 times the upper limit of normal values.

If hypercalcemia develops, the drug should be discontinued immediately until serum calcium levels normalize, and treatment can resume at a lower initial dose. In patients receiving dialysis, serum calcium, phosphorus, magnesium, and alkaline phosphatase must be monitored periodically. In patients with hypoparathyroidism, serum calcium, phosphorus, and 24-hour urinary calcium levels must be regularly monitored. In predialysis patients, serum calcium, phosphorous, alkaline phosphatase, creatinine, and intact PTH are compared at baseline and then monthly for 6 months. Therapeutic effectiveness requires a minimum of 600 mg of calcium intake daily, with the recommended dietary allowance for calcium in adults being 800 to 1200 mg.[30] Monitor the Psoriasis Symptom Inventory (PSI), Psoriasis Area and Severity Index (PASI), and The Dermatology Life Quality Index (DLQI) in patients with psoriasis.[7]

Toxicity

Signs and Symptoms of Overdose

The median lethal dose for oral administration in rats is 620 μg/kg, and the median lethal dose for intraperitoneal administration is greater than 5 mg/kg. Overdose symptoms of hypercalcemia include anorexia, nausea, vomiting, polyuria, polydipsia, and weakness.[31]

Management of Overdose

Treatment for calcitriol overdose includes general supportive measures. Immediate discontinuation of calcitriol and a low-calcium diet is recommended. The initial treatment for symptomatic or severe hypercalcemia typically involves hydration and intravenous bisphosphonates, such as zoledronic acid or pamidronate. For patients with renal impairment, denosumab and dialysis may be required.[31] Drugs like phosphates and corticosteroids may help induce excretion and forced diuresis in persistent, elevated calcium levels. One hypothesis involves ketoconazole or fluconazole, which inhibit CYP27B1, and can be effective in cases of calcitriol toxicity; further research is required.[32] Consult a toxicologist or poison control center for the latest recommendations.

Enhancing Healthcare Team Outcomes

Calcitriol is a widely prescribed agent by primary care providers, nurse practitioners, endocrinologists, dermatologists, and internists. However, therapy with the drug requires an entire interprofessional healthcare team, including clinicians, nurses, and pharmacists. While calcitriol is relatively safe, patients must be monitored for adverse effects, the most common of which is hypercalcemia. Patients may present with hypertension, renal stones, behavior alterations, and severe constipation. At each clinic visit, the healthcare provider should ask for symptoms of hypercalcemia. In some patients, regular monitoring of calcium levels may be required.[33] Endocrinologists, nephrologists, and dermatologists initiate calcitriol treatment based on clinical diagnosis. Resident physicians carry out follow-ups of the patients and therapy adjustments as indicated. Physician assistants and nurse practitioners follow the patient's response to treatment and accordingly adjust in consultation with the clinical team. Pharmacists check proper dosing and monitor drug interaction. Nurses deliver the treatment, monitor adverse effects, and support patients during treatment. For patients experiencing an overdose, emergency medicine and critical care physicians must be quick to treat acute conditions and keep the patient stable in hypercalcemia. The collaborative interprofessional efforts of clinicians, nurses, and pharmacists significantly enhance patient outcomes while minimizing the risk of adverse effects related to calcitriol therapy.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Uenishi K, Tokiwa M, Kato S, Shiraki M. Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis. Osteoporos Int. 2018 Mar;29(3):723-732. [PMC free article: PMC5834567] [PubMed: 29273827]

2.

Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT. Management of Hypoparathyroidism: Summary Statement and Guidelines. J Clin Endocrinol Metab. 2016 Jun;101(6):2273-83. [PubMed: 26943719]

3.

Locantore P, Oliva A, Cera G, Paragliola RM, Novizio R, Policola C, Corsello A, Pontecorvi A. Hypercalcemia Following Adrenalectomy for Cushing Syndrome in a Patient with Post-Surgical Hypoparathyroidism. Diseases. 2025 Jan 17;13(1) [PMC free article: PMC11765226] [PubMed: 39851484]

4.

Dadkhah PA, Farshid A, Khademi R, Yaghoubi S, Asadzadeh A, Moharamnejad N, Jadidian F, Ziaei SA, Haghshoar S, Salimi O, Shafagh SG, Rabiei N, Shahsavari S, Shokravi S, Maroufi Z, Deravi N, Erabi G, Naziri M. Impact of oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy: Systematic review and meta-analysis. Scand J Surg. 2024 Dec;113(4):263-272. [PubMed: 38785032]

5.

Kravvas G, Gholam K. Use of topical therapies for pediatric psoriasis: A systematic review. Pediatr Dermatol. 2018 May;35(3):296-302. [PubMed: 29493005]

6.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017 Jul;7(1):1-59. [PMC free article: PMC6340919] [PubMed: 30675420]

7.

Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober B, Wu JJ, Hariharan V, Menter A. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021 Feb;84(2):432-470. [PubMed: 32738429]

8.

Saha S, Sreenivas V, Goswami R. Alfacalcidol vs Calcitriol in the Management of Patient With Hypoparathyroidism: A Randomized Controlled Trial. J Clin Endocrinol Metab. 2021 Jun 16;106(7):2092-2102. [PubMed: 33616655]

9.

Sarathi V, Dhananjaya MS, Karlekar M, Lila AR. Vitamin D deficiency or resistance and hypophosphatemia. Best Pract Res Clin Endocrinol Metab. 2024 Mar;38(2):101876. [PubMed: 38365463]

10.

Grover M, Maahs DM. 50 Years Ago in TheJournalofPediatrics: Advances in Diagnosis and Treatment of Pseudovitamin D Deficiency Rickets. J Pediatr. 2020 Jun;221:200. [PubMed: 32446481]

11.

Jin C, Zhang C, Ni X, Zhao Z, Xu L, Wu B, Chi Y, Jiajue R, Jiang Y, Wang O, Li M, Xing X, Meng X, Xia W. The efficacy and safety of different doses of calcitriol combined with neutral phosphate in X-linked hypophosphatemia: a prospective study. Osteoporos Int. 2022 Jun;33(6):1385-1395. [PMC free article: PMC9106624] [PubMed: 35088103]

12.

Lie E, Choi M, Wang SP, Eichenfield LF. Topical Management of Pediatric Psoriasis: A Review of New Developments and Existing Therapies. Paediatr Drugs. 2024 Jan;26(1):9-18. [PMC free article: PMC10769900] [PubMed: 37847480]

13.

Alemany-Perna B, Tamarit J, Cabiscol E, Delaspre F, Miguela A, Huertas-Pons JM, Quiroga-Varela A, Merchan Ruiz M, López Domínguez D, Ramió I Torrentà L, Genís D, Ros J. Calcitriol Treatment Is Safe and Increases Frataxin Levels in Friedreich Ataxia Patients. Mov Disord. 2024 Jul;39(7):1099-1108. [PubMed: 38696306]

14.

Chakraborty D, Aggarwal K. Comparative evaluation of efficacy and safety of calcipotriol versus calcitriol ointment, both in combination with narrow-band ultraviolet B phototherapy in the treatment of stable plaque psoriasis. Photodermatol Photoimmunol Photomed. 2023 Sep;39(5):512-519. [PubMed: 37293775]

15.

Ben-Eltriki M, Deb S, Guns ES. Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions. J Cancer. 2016;7(4):391-407. [PMC free article: PMC4749360] [PubMed: 26918053]

16.

Akagi Y, Nagata A, Odagi M, Nagasawa K. Synthetic studies of (23S,25R)-1α,25-dihydroxyvitamin D₃ 26,23-lactone (calcitriol lactone) and its derivatives. J Steroid Biochem Mol Biol. 2018 Mar;177:240-246. [PubMed: 28757443]

17.

Nagata A, Akagi Y, Masoud SS, Yamanaka M, Kittaka A, Uesugi M, Odagi M, Nagasawa K. Stereoselective Synthesis of Four Calcitriol Lactone Diastereomers at C23 and C25. J Org Chem. 2019 Jun 21;84(12):7630-7641. [PubMed: 30985122]

18.

Kong M, Zhu L, Bai L, Zhang X, Chen Y, Liu S, Zheng S, Pandol SJ, Han YP, Duan Z. Vitamin D deficiency promotes nonalcoholic steatohepatitis through impaired enterohepatic circulation in animal model. Am J Physiol Gastrointest Liver Physiol. 2014 Nov 01;307(9):G883-93. [PMC free article: PMC4216990] [PubMed: 25214402]

19.

Rinella ME. Examining the Nomenclature Change From NAFLD and NASH to MASLD and MASH. Gastroenterol Hepatol (N Y). 2023 Nov;19(11):697-699. [PMC free article: PMC10882866] [PubMed: 38405223]

20.

Monastra G, De Grazia S, De Luca L, Vittorio S, Unfer V. Vitamin D: a steroid hormone with progesterone-like activity. Eur Rev Med Pharmacol Sci. 2018 Apr;22(8):2502-2512. [PubMed: 29762856]

21.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Sep 15, 2025. Calcitriol. [PubMed: 30000755]

22.

Karras SN, Wagner CL, Castracane VD. Understanding vitamin D metabolism in pregnancy: From physiology to pathophysiology and clinical outcomes. Metabolism. 2018 Sep;86:112-123. [PubMed: 29066285]

23.

Zhou L, Taylor-Miller T, Zacharin M, Efron D. Extreme hypercalcaemia due to accidental vitamin D intoxication. J Paediatr Child Health. 2019 Jan;55(1):104-106. [PubMed: 30024081]

24.

Yip KH, Kolesnikoff N, Yu C, Hauschild N, Taing H, Biggs L, Goltzman D, Gregory PA, Anderson PH, Samuel MS, Galli SJ, Lopez AF, Grimbaldeston MA. Mechanisms of vitamin D₃ metabolite repression of IgE-dependent mast cell activation. J Allergy Clin Immunol. 2014 May;133(5):1356-64, 1364.e1-14. [PMC free article: PMC4154631] [PubMed: 24461581]

25.

Robien K, Oppeneer SJ, Kelly JA, Hamilton-Reeves JM. Drug-vitamin D interactions: a systematic review of the literature. Nutr Clin Pract. 2013 Apr;28(2):194-208. [PMC free article: PMC5623087] [PubMed: 23307906]

26.

Kota BP, Abdul MI, Allen JD, Kalagara M, Roufogalis BD. Effect of vitamin D3 supplementation on the pharmacokinetics of digoxin--a pilot study. Fundam Clin Pharmacol. 2012 Aug;26(4):543-8. [PubMed: 21477267]

27.

El-Hajj Fuleihan G, Clines GA, Hu MI, Marcocci C, Murad MH, Piggott T, Van Poznak C, Wu JY, Drake MT. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023 Feb 15;108(3):507-528. [PubMed: 36545746]

28.

L A, Viswanath S A, G NG, Jeyasekharan R, David D, Ovett JJ. An Interesting Case of Vitamin D-Mediated Severe Hypercalcemia in a Patient With Renal Mass. JCEM Case Rep. 2025 Jan;3(1):luae233. [PMC free article: PMC11738643] [PubMed: 39830969]

29.

Jean G, Souberbielle JC, Chazot C. Vitamin D in Chronic Kidney Disease and Dialysis Patients. Nutrients. 2017 Mar 25;9(4) [PMC free article: PMC5409667] [PubMed: 28346348]

30.

Awadh AA, Hilleman DE, Knezevich E, Malesker MA, Gallagher JC. Vitamin D supplements: The pharmacists' perspective. J Am Pharm Assoc (2003). 2021 Jul-Aug;61(4):e191-e201. [PubMed: 33674204]

31.

Walker MD, Shane E. Hypercalcemia: A Review. JAMA. 2022 Oct 25;328(16):1624-1636. [PubMed: 36282253]

32.

Aberger S, Schreiber N, Pilz S, Eller K, Rosenkranz AR, Kirsch AH. Targeting Calcitriol Metabolism in Acute Vitamin D Toxicity-A Comprehensive Review and Clinical Insight. Int J Mol Sci. 2024 Sep 17;25(18) [PMC free article: PMC11431961] [PubMed: 39337491]

33.

Khan AA, Koch CA, Van Uum S, Baillargeon JP, Bollerslev J, Brandi ML, Marcocci C, Rejnmark L, Rizzoli R, Shrayyef MZ, Thakker R, Yildiz BO, Clarke B. Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. Eur J Endocrinol. 2019 Mar;180(3):P1-P22. [PMC free article: PMC6365672] [PubMed: 30540559]

Disclosure: Brandon Lung declares no relevant financial relationships with ineligible companies.

Disclosure: David E Komatsu declares no relevant financial relationships with ineligible companies.